Capital Bank & Trust CO Genmab A/S Transaction History

Capital Bank & Trust CO

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2020 Aug 14, 2020	SELL	$20.05 - $33.89 $42,786 - $72,321	-2,134 Closed	0 $0
Q1 2020 May 15, 2020	SELL	$17.15 - $25.22 $6,859 - $10,088	-400 Reduced 15.79%	2,134 $45,000
Q4 2019 Feb 18, 2020	SELL	$18.88 - $24.14 $472 - $603	-25 Reduced 0.98%	2,534 $57,000
Q3 2019 Nov 14, 2019	BUY	$18.0 - $21.38 $46,062 - $54,711	2,559 New	2,559 $52,000

236

52.5M

10.2K

25.5K

Ticker GMAB
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 658,292,992
Market Cap $13.6B
Description
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...

Get notified when there are updates to the investment portfolio of Capital Bank & Trust CO, based on Form 13F filings with the SEC.

Stay updated on Capital Bank & Trust CO with notifications on news.